Primary neuroendocrine carcinoma (NEC) in the liver is a rare entity that behaves aggressively. Primary hepatocellular carcinoma (HCC) with a NEC component is very rare, consisting of about 0.46% of primary hepatic tumors \[[@b1-jptm-2018-05-17]\]. Eighteen cases of primary combined or collided NEC and HCC have been reported in English literature to this date \[[@b1-jptm-2018-05-17]-[@b14-jptm-2018-05-17]\]. None of these cases had paraneoplastic syndromes or proved to be functional.

Hypercalcemia is a well-known paraneoplastic metabolic condition associated with many malignancies \[[@b15-jptm-2018-05-17]\]. In HCC, hypercalcemia accounts for 7.8% of the paraneoplastic syndromes \[[@b16-jptm-2018-05-17]\]. While primary hyperparathyroidism is the most common cause for hypercalcemia without malignancies, hypercalcemia can occur in association with malignancies through other mechanisms. Most of the malignancies associated with hypercalcemia proved to be caused by parathyroid hormone (PTH)--related peptide (PTHrP) \[[@b17-jptm-2018-05-17]\]. Metastasis of the malignancies to the bone can also cause osteolysis leading to hypercalcemia \[[@b17-jptm-2018-05-17]\]. Only rare cases are considered to be a result of ectopic PTH production by the tumors.

Here, we present a rare case of combined hepatic NEC and HCC with malignancy associated hypercalcemia caused by ectopic PTH production. Previously reported primary mixed HCC and NEC cases and ectopic PTH-producing HCC cases are also summarized and discussed.

CASE REPORT
===========

A 44-year-old man presented with a hepatic mass discovered during a regular abdominal ultrasound for hepatitis B virus associated chronic liver disease. The chronic liver disease was diagnosed 9 years ago and the patient was on Tenofovir. Laboratory findings showed elevated white blood cells (17,000/μL), mildly elevated aspartate aminotransferase (4 IU/L), alanine transaminase (22 IU/L), and normal calcium and phosphate levels. Computed tomographic scan identified one huge mass in segment (S) 8 and the other small mass in S6, with thrombi in right portal and hepatic veins. No other systemic lesion was found. The patient underwent right hemihepatectomy with partial diaphragm resection and lymph node dissection.

On pathological examination, the cut section of S8 revealed a yellow-whitish mass measuring 10.5 × 8.0 with irregular margins and necrosis. The mass in S6 was a yellowish multinodular mass that measured 1.3 × 1.0. Tumor thrombosis was noted in the right portal vein, and cirrhosis was observed in the nonneoplastic liver. Histologically, the main mass in S8 consisted of two components; a dominant poorly differentiated carcinoma component (60%) composed of small tumor cells with enlarged vesicular irregular nuclei, high nuclear to cytoplasmic ratio, large nucleoli, and frequent mitoses, and multiple foci of typical HCC component (40%) showing trabecular architecture and grade 2 nuclei ([Fig. 1](#f1-jptm-2018-05-17){ref-type="fig"}). The tumor penetrated the Glisson's capsule directly invading the diaphragm and showed extensive necrosis and microvessel invasion. The poorly differentiated carcinoma component was focally positive for cytokeratin (CK) 7 and negative for α-fetoprotein, hepatocyte, glypican-3, and CK19 immunohistochemistry, and was interpreted as poorly differentiated cholangiocarcinoma component. The pathologic diagnosis of S8 mass was combined HCC and cholangiocarcinoma. The other mass in S6 showed typical histologic features of HCC. There was no metastasis in 22 lymph nodes.

The patient subsequently received adjuvant concurrent chemoradiation therapy (CCRT) of one cycle of 5-flourouracil chemotherapy and two cycles of 5 fx radiation. On postoperative day 59, he visited the emergency room for nausea and vomiting. Laboratory results showed elevated levels of total calcium (13.2 mg/dL; normal range, 8.8 to 10.5), ionized calcium (2.3 mmol/L; normal range, 1.05 to 1.35), blood urea nitrogen (33 mg/dL; normal range, 10 to 26), and creatinine (2.16 mg/dL; normal range, 0.7 to 1.4) with normal to low levels of phosphate. Further evaluation of hypercalcemia revealed markedly increased PTH (3,859 by enzyme-linked immunosorbent assay; normal range, 15 to 65), and neuron-specific enolase (101.04 ng/mL; normal range, 0 to 16.3). Parathyroid scan was performed to exclude primary hyperparathyroidism, which showed no abnormality. Whole body positron emission tomography revealed multiple hypermetabolic lesions in the liver and whole skeleton, and biopsy of an osteolytic lesion involving a left rib discovered metastatic poorly differentiated carcinoma. Only the poorly differentiated carcinoma component, not the HCC component, was identified in the metastatic lesion. Regarding hypercalcemia, elevated PTH could not be explained with bone metastasis or PTHrP, and hypercalcemia persisted despite management. Finally, ectopic PTH production by the tumor was suggested as the cause of hypercalcemia.

Meanwhile, the clinician in charge enquired to the pathologist of the presence of NEC component in the tumor based on the possibility that ectopic hormone could be secreted by NEC, the rapid progression of the tumor and the elevated neuron-specific enolase level. Subsequent immunohistochemistry of neuroendocrine markers and PTH were performed on both primary (S8 mass) and metastatic tumor specimens. CD56 stained positive while chromogranin and synaptophysin were focally positive in the poorly differentiated area on both specimens, implying neuroendocrine differentiation ([Fig. 2](#f2-jptm-2018-05-17){ref-type="fig"}). The component with typical HCC morphology was negative for all three markers ([Fig. 2](#f2-jptm-2018-05-17){ref-type="fig"}). There was no immunoreactivity for PTH on either specimen. Symptomatic treatment including continuous renal replacement therapy was applied for the acute renal failure induced by hypercalcemia. However, the patient expired of disease progression 2 months after diagnosis.

This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-1801-442-702), and patient consent was waived.

DISCUSSION
==========

Primary combined HCC and NEC is very rare. The initial pathologic diagnosis of this case was combined HCC and cholangiocarcinoma because its poorly differentiated component bore little resemblance to typical NEC morphology. However, with clinical suspicion, immunohistochemistry revealed multifocal areas within the poorly differentiated component that stained positive for neuroendocrine markers. Therefore, we classified it as combined HCC and NEC.

The clinical characteristics of the 18 reported cases of primary mixed HCC and NEC are summarized in [Table 1](#t1-jptm-2018-05-17){ref-type="table"}. Most cases were associated with chronic hepatitis B or C. The reported carcinomas have been classified to two types according to its spatial histologic arrangement. Combined types have a transition zone in which HCC and NEC intermingle with each other whereas collision types show clear separation of the histologically different components, usually by fibrous septa. In our case, the HCC was tightly intermingled with the NEC component, their borders almost indiscernible due to transition zones. Therefore, we classified it as combined HCC and NEC.

Primary mixed HCC and NEC generally tend to have a poorer prognosis than conventional HCC \[[@b1-jptm-2018-05-17]\]. Of the 18 cases summarized, eight patients experienced recurrence, six patients died within the year of operation from the disease, and only two patients were confirmed to be alive 2 years after surgery ([Table 1](#t1-jptm-2018-05-17){ref-type="table"}). Remarkably, in the cases with biopsy-confirmed metastasis, the NEC component was solely found in all occasions, similar to the presenting case. This indicates that the NEC component acts more aggressively, which has a much poorer prognosis than primary HCC \[[@b1-jptm-2018-05-17]\]. Therefore, it is important to identify the neuroendocrine component and assure proper treatment be given to the patient.

None of the reported combined HCC-NEC described paraneoplastic syndrome or ectopic hormone production. To our knowledge, our case may be the first to report primary mixed HCC and NEC associated with malignancy-related hypercalcemia caused by ectopic PTH production. The patient had multiple bone metastases, and one of which was histologically confirmed. In hypercalcemia caused by osteolytic lesions or PTHrP produced by tumors, however, PTH levels are usually suppressed \[[@b15-jptm-2018-05-17]\]. It led us to favor ectopic PTH production to be the cause for hypercalcemia than bone metastasis or PTHrP, even though serum PTHrP level was not available.

The prevalence of hypercalcemia accounts for 7.8% of the paraneoplastic syndromes observed in HCC, and is associated with short survival \[[@b16-jptm-2018-05-17]\]. Ectopic PTH production has been reported in only three HCC cases ([Table 2](#t2-jptm-2018-05-17){ref-type="table"}) and not in any primary hepatic NEC case. All three cases performed PTH immunohistochemistry on their biopsy specimens which were negative. Our case also showed negative results. These findings, rather than acting as counter-evidence of hormone production, may suggest that the tumor cells do not store PTH but secrete it into circulation soon after synthesis \[[@b18-jptm-2018-05-17],[@b19-jptm-2018-05-17]\]. We were not able to perform genetic analysis or RNA sequencing for PTH mRNA. As hypercalcemia developed during adjuvant CCRT, comparison of intact PTH levels of before and after the operation or CCRT was impossible. However, in our case, the patient developed hypercalcemia with elevated intact PTH as the metastatic lesions formed. Considering that the metastatic component was NEC, it may be possible to suggest that the intact PTH was synthesized by the NEC cells.

Primary hepatic NEC has poor prognosis, and the NEC component of primary mixed HCC and NEC behaves aggressively. Clinicians and pathologists are advised to take caution for neuroendocrine differentiation when diagnosing poorly differentiated HCC.
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![Representative histologic image of the main hepatic mass.](jptm-2018-05-17f1){#f1-jptm-2018-05-17}

![(A) The main hepatic tumor consists of neuroendocrine carcinoma (right side) and hepatocellular carcinoma (left side) components. On immunohistochemistry, the neuroendocrine carcinoma component is focally positive for CD56 (B), chromogranin (C), and synaptophysin (D).](jptm-2018-05-17f2){#f2-jptm-2018-05-17}

###### 

Summary of previously reported primary mixed hepatocellular and neuroendocrine carcinoma cases

                                                     Age (yr)/sex   Chronic hepatitis type   Tumor size (cm)   Nodal metastasis   Type        Ectopic hormone production   Clinical course                Treatment                                                               Survival
  -------------------------------------------------- -------------- ------------------------ ----------------- ------------------ ----------- ---------------------------- ------------------------------ ----------------------------------------------------------------------- -----------------------
  Barsky *et al*. \[[@b2-jptm-2018-05-17]\]          43/M           B                        Large             Negative           Combined    None                         \-                             Chemotherapy (doxorubicin, 5-fluorouracil)                              Dead (26 mo)
  Artopoulos and Destuni \[[@b3-jptm-2018-05-17]\]   69/M           B                        10                Negative           Combined    None                         \-                             Surgery                                                                 Not given
  Ishida *et al*. \[[@b4-jptm-2018-05-17]\]          72/M           C                        3                 Positive (NEC)     Collision   None                         \-                             Surgery                                                                 Not given
  Yamaguchi *et al*. \[[@b5-jptm-2018-05-17]\]       71/M           C                        4.1               Negative           Combined    None                         Recurred (5 mo, bone)          Surgery                                                                 Alive (F/U 5 mo)
  Garcia *et al*. \[[@b6-jptm-2018-05-17]\]          50/M           C                        5.3               Negative           Collision   None                         Recurred (4 mo, liver)         Surgery → recur: chemotherapy (doxorubicin, thalidomide, bevacizumab)   Alive (F/U 16 mo)
  Yang *et al*. \[[@b7-jptm-2018-05-17]\]            65/M           B                        7.5               Positive (NEC)     Combined    None                         Recurred (3 mo, liver)         Surgery                                                                 Dead (12 mo)
  Tazi *et al*. \[[@b8-jptm-2018-05-17]\]            68/M           B                        4.0               Positive (NEC)     Collision   None                         \-                             Surgery → chemotherapy (cisplatin, etoposide)                           Alive (F/U 28 mo)
  Nakanishi *et al*. \[[@b9-jptm-2018-05-17]\]       76/M           C                        3.0               Negative           Combined    None                         Recurred (6 mo, bone)          TACE → surgery                                                          Dead (7 mo)
  Aboelenen *et al*. \[[@b10-jptm-2018-05-17]\]      51/M           C                        7.5               Negative           Combined    None                         \-                             Surgery                                                                 Alive (F/U 6 mo)
  Nishino *et al*. \[[@b11-jptm-2018-05-17]\]        72/M           C                        2.5               Negative           Combined    None                         Recurred (1 wk, lymph nodes)   Surgery → recur: chemotherapy (cisplatin, etoposide)                    Dead (2 mo)
  Nomura *et al*. \[[@b1-jptm-2018-05-17]\]          71/M           C                        4.1               Not given          Combined    None                         Recurred (liver)               Surgery                                                                 Dead (8 mo)
  Nomura *et al*. \[[@b1-jptm-2018-05-17]\]          71/M           C                        3.0               Not given          Collision   None                         Recurred (liver)               RFA → surgery                                                           Dead (2 mo)
  Nomura *et al*. \[[@b1-jptm-2018-05-17]\]          58/M           B                        4.3               Not given          Combined    None                         \-                             Surgery                                                                 Alive (F/U 20 mo)
  Nomura *et al*. \[[@b1-jptm-2018-05-17]\]          50/M           B                        1.8               Not given          Combined    None                         \-                             Surgery                                                                 Alive (F/U 19 mo)
  Nomura *et al*. \[[@b1-jptm-2018-05-17]\]          63/M           C                        3.0               Not given          Combined    None                         \-                             IFN → surgery                                                           Alive (24 mo)
  Baker *et al*. \[[@b12-jptm-2018-05-17]\]          76/M           None                     5.5               Negative           Collision   None                         \-                             Surgery → chemotherapy (platinum-based)                                 Alive (F/U not given)
  Choi *et al*. \[[@b13-jptm-2018-05-17]\]           72/M           C                        2.5               Negative           Collision   None                         Recurred (6 mo, liver)         Surgery → recur: chemotherapy (cisplatin, etoposide)                    Alive (F/U 10 mo)
  Liu *et al*. \[[@b14-jptm-2018-05-17]\]            65/M           C                        4.3               Positive (NEC)     Collision   None                         \-                             Surgery                                                                 Dead (1.3 mo)

M, male; NEC, neuroendocrine carcinoma; F/U, follow-up; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; IFN, interferon therapy.

###### 

Summary of previously reported hepatocellular carcinoma cases with ectopic PTH production

                                                     Age/Sex   Chronic hepatitis type   Hepatocellular carcinoma                             Initial laboratory findings   Parathyroid lesion   Treatment           Method of ectopic PTH confirmation   Survival                                                                                                   
  -------------------------------------------------- --------- ------------------------ ---------------------------------------------------- ----------------------------- -------------------- ------------------- ------------------------------------ --------------------- -------------------------------- --------------------------------------------------- -------------------
  Koyama *et al*. \[[@b20-jptm-2018-05-17]\]         83/M      C                        Single 8 cm mass                                     13 (8.9--10.1)                360 (15--50)         18.7 (13.8--55.3)   29.348 (0--10)                       None                  TAE                              Venous sampling                                     Alive (F/U 24 mo)
  Decreased serum calcium and intact PTH after TAE                                                                                                                                                                                                                                                                                                                  
  Mahoney *et al*. \[[@b19-jptm-2018-05-17]\]        72/M      None                     Multiple large lesions, extending into portal vein   14.5 (8.5--10.5)              92 (12--65)          \< 0.7 (\< 1.3)     Not given                            Parathyroid adenoma   Parathyroid resection and TACE   Sestamibi SPECT scan                                Dead (not given)
  Immunoradiometric assay and rapid assay                                                                                                                                                                                                                                                                                                                           
  Abe *et al*. \[[@b18-jptm-2018-05-17]\]            73/F      B                        Large mass with multiple metastasis                  12.9 (8.5--10.5)              99 (\< 60)           \< 1 (not given)    189.3 (not given)                    None                  TACE                             Decreased serum calcium and intact PTH after TACE   Dead (2 mo)

PTH, parathyroid hormone; PTHrP, PTH-related peptide; AFP, α-fetoprotein; M, male; TAE, transcatheter arterial embolization; F/U, follow-up; TACE, transarterial chemoembolization; SPECT, single-photon emission computed tomographic.
